StockData
Immuron Ltd logo

Immuron Ltd (IMRN) stock

IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30
$0.87−0.03 (-3.20%)

Close on Nov 17, 2026Market cap $7.03MP/E –Yield –

Immuron r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was A$1.93M, down 46.3% from the year before. Over ten years it grew -6.1% a year on average. The highest annual figure on record is A$5.38M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026A$1.93M-46.3%
FY2025Jun 30, 2025A$3.60M-33.1%
FY2024Jun 30, 2024A$5.38M+107.4%
FY2023Jun 30, 2023A$2.59M+294.1%
FY2022Jun 30, 2022A$657.72K-51.9%
FY2021Jun 30, 2021A$1.37M+16.0%
FY2020Jun 30, 2020A$1.18M+12.8%
FY2019Jun 30, 2019A$1.04M-53.7%
FY2018Jun 30, 2018A$2.26M-51.3%
FY2017Jun 30, 2017A$4.63M+27.8%
FY2016Jun 30, 2016A$3.62M–

More Immuron figures

See a number that looks wrong?